Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (NCT05317416)
A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years
Who can join: Review the eligibility criteria below.
Location: Banner Gateway Medical Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (209 Sites)
Showing the first 25 of 209 sites.
- Banner Gateway Medical Center — Gilbert, Arizona
- Banner Gateway Medical Pavilion — Gilbert, Arizona
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Ronald Reagan UCLA Medical Center — Los Angeles, California
- UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California
- UCLA Hematology/Oncology — Los Angeles, California
- Santa Monica UCLA Medical Center & Orthopaedic Hospital — Santa Monica, California
- UCLA Hematology/Oncology - Santa Monica — Santa Monica, California
- Georgetown University Medical Center — Washington D.C., District of Columbia
- Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- Loyola University Chicago — Maywood, Illinois
- Ascentist Doctor Hospital — Leawood, Kansas
- University of Michigan — Ann Arbor, Michigan
- American Oncology Partners, P.A. Dba MidAmerica Cancer Care — Kansas City, Missouri
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
- WMCHealth Advanced Physician Services — Hawthorne, New York
- Westchester Medical Center — Valhalla, New York
- Cleveland Clinic — Cleveland, Ohio
- OhioHealth Arthur G.H. Bing, MD, Cancer Center — Columbus, Ohio
- OhioHealth Research Institute — Columbus, Ohio
- OhioHealth Riverside Methodist Hospital — Columbus, Ohio
- Baylor University Medical Center — Dallas, Texas
- Baylor Scott & White Medical Center - Temple — Temple, Texas
- Royal Prince Alfred Hospital — Camperdown, New South Wales
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.